Exscientia plc

Exscientia plc (EXAI) priced its initial public offering on Oct 4, 2021 at $22.00 per ADS, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $2.6B. Goldman Sachs was lead-left underwriter, joined by Morgan Stanley, BofA Securities and Barclays. Cooley advised the company and Goodwin Procter advised the underwriters.

Exscientia plc is an artificial intelligence-driven pharmatech company that designs and develops drugs. It has built an end-to-end solution combining AI and experimental technologies for target selection and drug design, aiming to improve the probability, speed and cost of creating medicines.

Status

IPO

Ticker

EXAI

Exchange

Nasdaq Global Select

Priced

Oct 4, 2021

IPO price

$22.00 per ADS

Market cap at IPO price

$2.6B

First filed

Sep 10, 2021

Underwriters

Goldman Sachs, Morgan Stanley, BofA Securities and Barclays

Company counsel

Cooley

Underwriters' counsel

Goodwin Procter

Sector

Biotech & pharma

Country / state

United Kingdom

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.